- AU$135.09m
- AU$96.64m
- AU$5.91m
Brief: Dimerix Ltd Licenses Dmx200 To Everest For China And Asia Region
Brief: Everest Medicine In Agreement With Dimerix To Develop Commercialize DMX-200 In Greater China, South Korea, And Southeast Asia
Brief: Dimerix Seeks Trading Halt
Brief: Dimerix To Conduct Review Of Action3 Statistical Assumptions
Brief: Dimerix Loss For Half-Year Attributable A$16 Million
Brief: Dimerix Appoints Mike Tonroe As CFO
Australia's Dimerix hits 7-month high on $4.8 billion sale
Australia's Dimerix rises as kidney disease drug receives 'orphan' status in Japan
Brief: Dimerix Says Dmx-200 Receives Orphan Drug Designation In Japan
Brief: Dimerix Receives Upfront Payment Of $30 Million From Amicus Therapeutics
Australia's Dimerix hits nearly 5-year high on US license for its drug
Brief: Dimerix And Amicus Therapeutics Announce Exclusive License Agreement For DMX-200 In United States
Brief: Dimerix Seeks Trading Halt
Brief: Dimerix Receives Initial Upfront Payment From FUSO
Brief: Dimerix Logs Loss For Half-Year Attributable A$12.9 Mln
Brief: Dimerix And FUSO Enter Into Exclusive Development And License Agreement To Commercialise DMX-200 In Japan
Australia's Dimerix jumps most in 1 year on drug development agreement for Japan
Australia's Dimerix climbs on license deal to commercialize drug in Middle East
Brief: Dimerix Says Taiba Acquires Exclusive Rights To Register, Commercialise DMX-200